Revvity, IncNYSE: RVTY

No material news in the last 48 hours.

No material news in the last 48 hours.

No material news in the last 48 hours.

No material news in the last 48 hours.

No material news in the last 48 hours.

Barclays analyst Luke Sergott downgraded Revvity to Equal Weight from Overweight and slashed his price target to $95 from $118. In contrast, TD Cowen's Dan Brennan raised his price target to $120 from $115 with a Buy rating. The bearish action follows Q1 2026 results showing non-GAAP EPS of $1.06 (beat by $0.02) on revenue of $711.1M that missed estimates. Revvity's full-year 2026 revenue guidance of $2.81-$2.84B came in about 5% below consensus, with pro forma organic growth of 3-4% and adjusted EPS of $5.20-$5.30, excluding the planned divestiture of its China Immunodiagnostics unit. The Immunodiagnostic Systems unit secured FDA clearance for a Total Testosterone automated chemiluminescence immunoassay.

Revvity (RVTY) Is Down 5.0% After Raising 2026 Outlook And Securing FDA Assay Clearancesimplywall.stRevvity outlines 3%-4% 2026 organic growth and $5.20-$5.30 EPS while planning China immunodiagnostics divestitureseekingalpha.comRVTY Q1 2026 Deep Dive: Portfolio Pruning and AI Investments Shape Outlookstockstory.org

Revvity reported Q1 2026 revenue of $686.9 million, up 9.3% YoY but short of the $705.1 million consensus, while non-GAAP EPS of $1.06 beat by 4.5%. The company announced plans to divest its China immunodiagnostics business (about 6% of 2025 revenue), with closure anticipated by end of 2027. Revvity received FDA clearance for its Total Testosterone automated chemiluminescence immunoassay, complementing its existing FDA-cleared testosterone-related tests. The company also launched Xynthetica (AI-as-a-service), Signals BioDesign, and the Opera Phenix OptIQ high-content screening system. Multiple analysts cut price targets, including Baird to $117 from $125, Stifel to $100 from $110, and JPMorgan to $90 from $96. Full-year 2026 guidance midpoint of $2.83B came in roughly 5% below Street estimates.

Revvity Q1 2026 slides revenue beats margininvesting.comRVTY Q1 2026 Portfolio Pruning AI Investmentsstockstory.orgFDA Clears Revvity Total Testosteroneclpmag.com

Revvity reported Q1 2026 results on May 5, with revenue up 7% to $711M (vs. $704M FactSet consensus) and non-GAAP EPS of $1.06, beating the $1.02-1.04 estimate. Operating margin expanded to 23.6%, above its 23% prior expectation. The company plans to divest its China Immunodiagnostics business, which represented roughly 6% of 2025 revenue, with a close expected by end of 2027. FY26 pro-forma guidance was set to $2.81-2.84B in revenue with adjusted EPS of $5.20-5.30, which came in about 5% below Street estimates and prompted multiple analyst price-target cuts. The FDA also cleared Revvity's Total Testosterone ChLIA automated immunoassay in May 2026. Management presented at the BofA Global Healthcare Conference on May 13.

Revvity Announces Financial Results for the First Quarter of 2026businesswire.comRevvity Q1 2026 Deep Dive: Portfolio Pruning and AI Investments Shape Outlookstockstory.orgFDA Clears Revvity Total Testosterone Assay for Automated Testingclpmag.com

T. Rowe Price disclosed beneficial ownership of 10.1 million Revvity shares (9.0%) in an amended Schedule 13G/A filed on May 15, 2026. Revvity presented at the Bank of America Global Healthcare Conference on May 13, 2026, following Q1 results on May 5 that beat EPS expectations at $1.06 versus $1.04 consensus, with revenue up 9.3% YoY to $686.9 million. Management announced a planned divestiture of its China immunodiagnostics business (6% of 2025 revenue) expected to close by end of 2027 to streamline operations. Full-year 2026 guidance was updated on a pro forma basis to $2.81B-$2.84B revenue and $5.20-$5.30 adjusted EPS, with the midpoint coming in 5.2% below consensus. The company launched Opera Phenix OptIQ high-content screening system and Signals BioDesign biologics software.

Revvity stock: T. Rowe Price reports a 9% stakead-hoc-news.deT. Rowe Price reports 10.1M Revvity shares (9.0%)stocktitan.netRevvity Q1 2026 slides: revenue beats amid margin pressure, China exitinvesting.com

Revvity reported Q1 2026 results on May 6, 2026 with sales of $686.9 million, up 9.3% YoY, and non-GAAP EPS of $1.06 (4.5% above consensus). Full-year revenue guidance of $2.83 billion midpoint came in 5.2% below analyst estimates. FY26 EPS guidance set at $5.20-$5.30. The company secured FDA clearance for a new testosterone testing solution and announced plans to divest its immunodiagnostics business in China to enhance growth rates and margins. Stock trades at $97.76, up from $86.51 just before earnings. Analyst PT cuts as of May 15: Baird $125 to $117, Stifel $110 to $100, JPMorgan $96 to $90.

RVTY Q1 2026 Deep Dive - StockStorystockstory.orgRevvity outlines 3%-4% 2026 organic growth - Seeking Alphaseekingalpha.comRevvity Q1 2026 slides - Investing.cominvesting.com

Revvity reported Q1 2026 results on May 5, 2026 with revenue of $711M (up from $665M YoY) and adjusted EPS of $1.06 beating the $1.02 consensus. The company announced a strategic decision to divest its immunodiagnostics business in China, representing a major portfolio optimization move. 2026 guidance projects total revenue of $2.81-$2.84B (4-5% growth, 3-4% organic) and adjusted EPS of $5.20-$5.30. Revvity presented at the Bank of America Global Healthcare Conference on May 13, 2026. Multiple analysts cut price targets post-earnings: Baird to $117 from $125, Stifel to $100 from $110, JPMorgan to $90 from $96, while Barclays raised to $105 from $95 and TD Cowen raised to $120 from $115. Revvity also secured FDA clearance for a new testosterone testing solution and announced an Eli Lilly TuneLab collaboration. Mixed sentiment as China exit and downward revenue guide weigh on outlook.

Revvity Announces Q1 2026 Financial Resultsbusinesswire.comRevvity Q1 2026 slides: revenue beats amid margin pressure, China exitinvesting.comRevvity Bank of America Global Healthcare Conference 2026seekingalpha.com

Revvity will present at the BofA Securities 2026 Health Care Conference on Wednesday, May 13, 2026 at 9:20 a.m. PT, providing a near-term catalyst for management commentary on its updated 2026 outlook. The company reported Q1 2026 revenue of $711.1 million (+7% YoY) and adjusted EPS of $1.06, beating consensus of $1.02. Revvity reaffirmed pro forma 2026 guidance of $2.81-$2.84 billion revenue and adjusted EPS of $5.20-$5.30, while signaling its planned divestiture of the China immunodiagnostics business (about 4.5% of expected 2026 revenue) to focus on higher-return areas. Additionally, Rep. Gilbert Ray Cisneros, Jr. disclosed an acquisition of RVTY stock on May 12, 2026, a notable Congressional trading signal. Risk includes execution of portfolio pruning and margin pressure from the China exit.

Revvity investor conference talks set for May 13, June 9stocktitan.netRevvity (NYSE:RVTY) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.americanbankingnews.comRevvity outlines 3%-4% 2026 organic growth and $5.20-$5.30 EPS while planning China immunodiagnostics divestitureseekingalpha.com

A May 12 disclosure showed Rep. Gilbert Ray Cisneros, Jr. acquired Revvity shares, a modest political-insider signal flagged by trackers. The disclosure lands one day before Revvity's BofA Securities 2026 Healthcare Conference presentation on May 13 at 9:20am PT. Context: Revvity's May 5 Q1 print beat with revenue of $711M and adjusted EPS of $1.06, but full-year revenue guidance of $2.81-2.84B came in ~5% below consensus due to the planned China immunodiagnostics divestiture. Bear case: management cut FY revenue and the China exit removes ~4.5% of expected 2026 revenue.

Revvity Stock Acquired by Rep. Gilbert Ray Cisneros, Jr.americanbankingnews.comRevvity investor conference talks set for May 13, June 9stocktitan.net